SWECO introduces LA Separator

Published: 18-Aug-2011
Manufacturing Active Nutrition Food

Low profile machine offers a sifting motion across the screen plane

SWECO introduces LA Separator
SWECO, a US supplier of particle separation and size reduction systems, has added the LA Separator to its portfolio for the pharmaceutical and food and beverage industries.

The LA Separator features a single vertically mounted motor to induce a sifting motion across the screen plane. The frames of the separator are mounted on rubber isolators compared with the springs used in conventional low profile and other standard separators. Additionally, the LA Separator runs at higher G loadings and speeds than traditional low profile models.

The sifting motion is suitable for dealing with lighter products such as flours and starches. Rates of up to x8 those of other conventional low profile separators have been achieved.

For some scalping applications, other low profile designs can place too much vertical action on the product, greatly reducing the process rate. The LA Separator’s horizontal, high G motion increases the capacity of the undersize product passing through the screen, while allowing the oversize material to exit the separator.

SWECO, headquartered in Florence, KY, serves the chemical, food, pharmaceutical, minerals, paper and many other industries with separation, sizing and milling equipment.

See more

You may also like

Manufacturing
Patented device reinvents Solid Phase Extraction

Patented device reinvents Solid Phase Extraction

Read more
Biotech Fluidics announce SPEedy - a device that provides an effortless way to perform Solid Phase Extraction (SPE) sample preparation procedures without need of an external vacuum and compatible with any adsorption chemistry or eluent composition

Trending Articles

  1. Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite The multi-million-pound expansion adds a 1400 sqft Grade C cleanroom, OEB5 containment handling and a 3400 sqft analytical laboratory — extending Sterling's bioconjugation capability from development through to Phase III and commercial scale
  2. FDA inspection readiness: Preparing for surveillance and pre-approval inspections Preparing pharma and biotech teams for continuous FDA inspection readiness, mock inspections and proactive regulatory risk management
  3. Hovione to install first ConsiGma CDC Flex continuous tableting line in US The CDMO is investing $35m in a next-generation continuous tableting line at its 89 Twin Rivers facility in New Jersey, creating an integrated US pathway from spray-dried amorphous solid dispersions to commercial tablet production
  4. SCHOTT Pharma makes decarbonisation measurable Validated carbon footprint tool supports informed Scope 3 reduction decisions for pharmaceutical packaging
  5. FDA Form 483 explained: responding to findings and managing regulatory risk Explore what a Form FDA 483 means, how to respond within 15 business days, assess patient risk, address observations and understand how FDA evaluates responses and inspection outcomes

You may also like

Manufacturing
Patented device reinvents Solid Phase Extraction

Patented device reinvents Solid Phase Extraction

Biotech Fluidics announce SPEedy - a device that provides an effortless way to perform Solid Phase Extraction (SPE) sample preparation procedures without need of an external vacuum and compatible with any adsorption chemistry or eluent composition
Manufacturing
Orano Med inaugurates Europe's first industrial-scale lead-212 radioligand therapy facility

Orano Med inaugurates Europe's first industrial-scale lead-212 radioligand therapy facility

The €29m ATLab site will target up to 10,000 doses annually and its two-hour proximity to major European airports meets the critical 24-hour production-to-administration window imposed by lead-212's 10.6-hour half-life
Manufacturing
Lonza advances aseptic spray drying for high-dose biologics

Lonza advances aseptic spray drying for high-dose biologics

This new technology platform addresses stability, concentration, and delivery challenges in biologics, including new modalities
Manufacturing
Catalent launches ten-month gene-to-drug substance programme for complex biologics

Catalent launches ten-month gene-to-drug substance programme for complex biologics

The accelerated pathway extends the CDMO's Rapid Antibody framework to bispecifics and next-generation formats — targeting master cell bank release by month seven and bulk drug substance lot release by month ten
Design & Build
Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite

Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite

The multi-million-pound expansion adds a 1400 sqft Grade C cleanroom, OEB5 containment handling and a 3400 sqft analytical laboratory — extending Sterling's bioconjugation capability from development through to Phase III and commercial scale
Manufacturing
Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month

Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month

Piramal Pharma Solutions (“PPS”), a leading global Contract Development and Manufacturing Organisation (CDMO) and part of Piramal Pharma Ltd. (“PPL”) (NSE: PPLPHARMA | BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug cyclophosphamide in October
Manufacturing
Why your coating process is less consistent than you think - and what to do about it

Why your coating process is less consistent than you think - and what to do about it

Tablet coating defects rarely begin at the coating stage. In this live webinar, industry expert Fred Rowley examines the upstream variables - suspension handling, spray-rate stability, gun pattern verification - that determine whether a coating process performs consistently at scale
Subscribe now